Navigation Links
Celebrex May Reduce Levels of Lung Cancer Biomarker
Date:6/1/2008

Anti-inflammatory might one day help prevent malignancies, study suggests

SUNDAY, June 1 (HealthDay News) -- A widely prescribed pain reliever may one day have value in helping to prevent lung cancer.

Researchers report that Celebrex (celecoxib), the last remaining cox-2 inhibitor on the U.S. market, may reduce levels of a biomarker indicating risk for this deadly disease. The team presented its findings Sunday at the American Society of Clinical Oncology annual meeting in Chicago.

They stressed that this doesn't mean people should start taking the drug for this reason, as Celebrex has noted cardiovascular side effects, albeit effects that were not seen in this short-term study.

"This is a very early study," said Dr. Shakun Malik, director of the lung cancer program at Georgetown's Lombardi Cancer Center, in Washington, D.C. "It hasn't shown any effect on actual lung cancer. All it is showing is that it affects biomarkers. The hypothesis is that if biomarkers are affected, it will help, but we haven't shown that as of yet."

The researchers agreed.

"We cannot sit here and say that taking celecoxib is going to prevent lung cancer," said study author Dr. Edward S. Kim, M.D., an assistant professor of thoracic head and neck medical oncology at the University of Texas M.D. Anderson Cancer Center in Houston. "What we do know was that Celebrex, when taken over a three- or six-month period, was safe to administer even at a higher dose of 800 milligrams daily."

"We certainly need to move forward with prospective validation," added Kim, who spoke at a Sunday news conference. In particular, researchers need to verify if reductions in biomarkers actually translate into a reduction in the risk of developing malignancies in the lung.

"It's too early to tell, but we're definitely interested in other trials to see how they make out with survival,' said Dr. Karen Reckamp, an assistant professor of medicine at City of Hope Cancer Center in Duarte, Calif.

Lung cancer is a notoriously difficult-to-treat disease, largely because it's usually not caught in its early stages.

"Lung cancer is an extraordinarily challenging tumor type," confirmed Dr. Howard Sandler, moderator of the news conference and a professor of radiation oncology and urology at the University of Michigan.

Prevention, therefore, becomes key. Quitting smoking or never smoking, of course, greatly reduces the risk for this disease. But there are people who beat the odds even if they smoke, just as there are nonsmokers who do develop lung cancer.

"We need to continue to refine what a high-risk population is, both clinical and biological characteristics, and that leads us into biomarkers," Kim said. The researchers were primarily interested in how Celebrex might affect Ki-67, a protein that may be related to cell proliferation.

The cox-2 enzyme is expressed in both precancerous lesions in lung tissue, as well as in lung cancer, and it has an inflammatory aspect that can stimulate more cell growth within the lung.

This study involved more than 200 patients, all of whom had a history (current or prior) of a greater than 20-pack-years cigarette habit. All participants underwent biopsies at the opening of the study, at three months and again at six months.

They were then randomized to take either Celebrex or a placebo for three months, after which they either continued on that course or switched to the other arm.

Over three months, high-dose Celebrex (400 milligrams twice a day) did reduce expression levels of Ki-67, as well as the cox-2 enzyme and a third biomarker, NF-kappa-B.

The effect was seen in both current and former smokers but was stronger in current smokers, Kim said.

No cardiac side effects were seen in the group, although previous research showed a benefit to Celebrex in reducing colon cancer but, at the same time, a significant increase in adverse events.

Kim hopes that future studies will identify patients at higher risk for heart problems (the greatest risk factor is age), and take that into account. It's also unclear at this point how long individuals should take Celebrex.

As for patients who already have the disease, Kim said, "I hope we can keep you alive until you have a heart attack, because that means we have treated your lung cancer very well."

Another study also presented at the meeting found that PET/CT (positron emission tomography/computed tomography) imaging more accurately staged lung cancer cases, sparing more patients from inappropriate surgery.

PET imaging identified 14 percent of patients who had cancer too advanced for surgery, while conventional work-ups only identified 7 percent of such patients for whom surgery would have been inappropriate.

"PET can replace conventional tagging in early stage non-small cell lung cancer," said study investigator Dr. Donna E. Maziak, of the Ontario Clinical Oncology Group in Hamilton, Ontario.

More information

Visit the National Cancer Institute for more on lung cancer.



SOURCES: June 1, 2008, news conference with Edward Kim, M.D., assistant professor, thoracic head and neck medical oncology, University of Texas M.D. Anderson Cancer Center, Houston, and Donna E. Maziak, M.D.C.M., Ontario Clinical Oncology Group, Hamilton, Ontario, Canada; Shakun Malik, director, lung cancer program, Lombardi Cancer Center, Georgetown University, Washington, D.C.; Karen Reckamp, assistant professor, medicine, City of Hope Cancer Center, Duarte, Calif.; June 1, 2008, presentations, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Celebrex-Lipitor combo may halt prostate cancer
2. Celebrex Plus Lipitor Could Fight Prostate Cancer
3. Celebrex, Naproxen Wont Prevent Mental Decline
4. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
5. New study: Pine bark reduces perimenopausal symptoms
6. Different method of evaluating the urinary tract system reduces radiation dose
7. Saline Reduces Mortality for Brain Injury Patients
8. New approaches to reduce scarring
9. Fruity vegetables and fish reduce asthma and allergies
10. New study: Pine bark extract reduces ADHD symptoms in children
11. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, ... addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization ... optimization products to the store is just one more way Shamangelic Healing supports ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... flexibility in repaying their loans, more information about their loan terms and accounts, ... outstanding student loan debt, including federal and private loans, has reached $1.3 trillion, ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 ... the Gloeckner Undergraduate Award, the Michelson People‚Äôs Choice Award, and the Committee Award ...
(Date:4/29/2016)... ... 2016 , ... Dr. Robert Mondavi, one of the dentists in Torrance ... a fast-growing field as more patients are discovering the many different ways they can ... options currently available to them and which ones might work for their smiles. ...
(Date:4/29/2016)... ... 29, 2016 , ... Innovations with Ed Begley Jr., announced ... airing third quarter 2016 via Discovery Channel. Dates and show times TBA. , ... located in Greenwood, Wisconsin applies product research and development and continuous technological improvements ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
Breaking Medicine Technology: